For instance, DNA methyltransferase inhibitors (DNMTis), such as decitabine (DAC), could restore tumor-associated antigen expression via promoter demethylation-mediated epigenetic reprogramming, thus enhancing CD19 CAR-T cell recognition and cytolytic activity (32); Changju Qu et al (33). The gene discussed is CD19; the disease is neoplasm.